Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. provided earnings guidance for the year ended December 31, 2021. The net profit attributable to the equity owners of EV MedTech for the year ended 31 December 2021 is expected to be between RMB 300.46 million and RMB 321.92 million, representing an increase of between 40% and 50% as compared with 2020. The net profit attributable to equity owners of EV MedTech after deducting extraordinary gains or losses is expected to be between RMB 276.85 million and RMB 295.94 million, representing an increase of between 45% and 55% as compared with 2020.

The main reason for the increase in profit was that in 2021, although there had been a recurrence of the COVID-19 epidemic, which to a certain degree impacted on the carrying out of surgical operations, the innovative products of EV MedTech, including Castor ® Branched Aortic Stent-Graft System, Minos Abdominal Aortic Stent-Graft and Delivery System and Reewarm PTX Drug Coated Balloon PTA Catheter have all continued rapid growth in 2021. These products have further consolidated and enhanced the competitiveness of EV MedTech in the aortic and peripheral interventional market. At the same time, with the continuous expansion of EV MedTech's innovative products in the international market, revenue from the overseas business has also achieved rapid growth.